Author:
Li Yan,Sun Shengnan,Zhang Hui,Jing Yongjian,Ji Xingzhao,Wan Qiang,Liu Yi
Abstract
Abstract
Background
Lung cancer is the second most common cancer with the highest mortality in the world. Calumenin as a molecular chaperone that not only binds various proteins within the endoplasmic reticulum but also plays crucial roles in diverse processes associated with tumor development. However, the regulatory mechanism of calumenin in lung adenocarcinoma remains elusive. Here, we studied the impact of calumenin on lung adenocarcinoma and explored possible mechanisms.
Methods
5-ethynyl-2’-deoxyuridine assay, colony formation, transwell and wound healing assays were performed to explore the effects of calumenin on the proliferation and migration of lung adenocarcinoma cells. To gain insights into the underlying mechanisms through which calumenin knockdown inhibits the migration and proliferation of lung adenocarcinoma, we performed Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, Gene Set Enrichment Analysis and Ingenuity Pathway Analysis based on transcriptomics by comparing calumenin knockdown with normal A549 cells.
Results
The mRNA and protein levels of calumenin in lung adenocarcinoma are highly expressed and they are related to an unfavorable prognosis in this disease. Calumenin enhances the proliferation and migration of A549 and H1299 cells. Gene Set Enrichment Analysis revealed that knockdown of calumenin in A549 cells significantly inhibited MYC and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog signaling pathways while activating interferon signals, inflammatory signals, and p53 pathways. Ingenuity pathway analysis provided additional insights, indicating that the interferon and inflammatory pathways were prominently activated upon calumenin knockdown in A549 cells.
Conclusions
The anti-cancer mechanism of calumenin knockdown might be related to the inhibition of MYC and KRAS signals but the activation of interferon signals, inflammatory signals and p53 pathways.
Funder
the Shandong Provincial Natural Science Foundation
the National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCA nestimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin. 2021;71:209–49.
2. Zou Y, Cao C, Wang Y, et al. Multi omics consensus portfolio to refine the classification of lung adenocarcinoma with prognostic stratification, tumor microenvironment, and unique sensitivity to first-line therapies. Transl Lung CancerRes. 2022;11:2243–60.
3. Thai Alesha A, Solomon Benjamin J, Sequist Lecia V, et al. Lung cancer. Lancet. 2021;398(10299):535–54.
4. Shi Y, Zhang X, Wu G, et al. Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): a multicenter prospective study. Lancet Reg Health West Pac. 2022;23:100452.
5. Tang S, Li S, Liu T, et al. MicroRNAs: emerging oncogenic and tumor suppressive regulators, biomarkers and therapeutic targets in lung cancer. Cancer Lett. 2021;502:71–83.